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Serum visfatin concentration in eutrophic  
and overweight/obese male children in early childhood
Abstract 
Background and Purpose: Childhood overweight/obesity is considered 
a global epidemic, which began earlier in pediatric patients and presents a 
major health risk in adulthood. It is well known that adipose tissue is an 
active endocrine inflammatory organ in obese adults, but its neurohormone 
activity in the childhood is not yet clarified. Visfatin is one of adipokines 
with insulin-mimetic and proinflammatory-atherosclerotic effect, whose role 
in the child’s age is still unknown as well as its physiological concentrations 
in serum of prepubertal children. The aim of this study was to determine 
visfatin serum concentration at the early age in eutrophic and overweight/
obese male children and its association with arterial blood pressure. 
Materials and Methods: Healthy boys, 2-14 years old, hospitalized for 
elective inguinal hernia surgery has been included in the study (N=31) and 
were divided into two groups according to percentile curve: a) overweight/
obese (O/O:above the 85th percentile) and  b) eutrophic (E:5th-85th per-
centile). Anthropometric and biochemical measurements and specific serum 
levels of visfatin by enzyme immunoassay were determined. 
Results and Conclusion: Both groups of examinees, eutrophic and over-
weight/obese, had a normal metabolic profile band on percentile ranks (fast-
ing glucose values and all fractions of lipid profile) and values of blood pressure. 
However overweight/obese boys had significant higher systolic blood pressure 
than eutrophic boys, p=0,028. Serum visfatin were 6.90±3.97 ng/ml in 
eutrophic boys, while in overweight/obese were 7.82±3.75 ng/ml, p=0,57. 
There is a tendency of visfatin serum concentration to increase with increase 
of body weight and growing. This suggests possible role of visfatin in future 
metabolic and cardiovascular processes related to increase in body mass. 
INTRoduCTIoN
Obesity is a complex clinical syndrome that represents a major, world public health problem (1). The childhood obesity with over-
weight is dramatically increased in industrial countries over the last 20 
years (1-4). Overweight is causing increased morbidity and mortality 
due to its association with insulin resistance, dyslipidemia, diabetes, 
hypertension and cardiovascular disease in adulthood (5-7). Over-
weight in adolescence is significantly correlated with obesity in adult-
hood (8, 9). In the childhood, obesity is defined as a body mass index 
(BMI) which is correlated with percentile curves by age and gender 
(above 95. percentile - obese, between the 85th-95th percentile - over-Received April 28, 2014.
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weight, below the 85th-5th percentiles - eutrophic chil-
dren) (10, 11).
Multiple factors lead to a high incidence of childhood 
obesity, genetic and external factors contribute to the de-
velopment of a high degree of obesity at an early age (12, 
13). Endocrine function of adipose tissue is achieved by 
synthesis of numerous adipocytokines such as leptin, 
adiponectin, resistin, vistin, adipsin, angiotensinogen, 
tumor necrosis factor a, interleukin-6, retinol-binding 
protein, plasminogen activator inhibitor-1, fibrinogen. 
The effect of listed adipocytes chemokine are realized by 
autocrine/paracrine and systemic effects, which means 
that they have their major effects locally as in distant tis-
sues and organs. Adipokines produced in adipose tissue 
have immunological, cardiovascular and metabolic func-
tions (14-16). Altered glucose metabolism, manifested as 
impaired glucose tolerance appears early in obese children 
and adolescents which is characterized by marked periph-
eral insulin resistance and a relative b-cell failure. Other 
elements of the metabolic syndrome, such as dyslipid-
emia, hypertension and markers of systemic ‘low-grade 
inflammation’ are already present in obese youngsters and 
worsen with the degree of obesity (17). 
The visfatin is an adipokine which was detected in 
peripheral lymphocytes (18). According to literature, vis-
fatin has a physiological role in the maturation of lym-
phocytes, inhibition of neutrophils apoptosis and biosyn-
thesis NAD (19). It has insulin mimetic activity, by 
binding to insulin receptors and mimic the effects of in-
sulin, causing hypoglycaemia (20). High expression of 
visfatin was observed in visceral adipose tissue (21). In 
tissues visfatin is found in the bones, liver, muscle, brain, 
kidneys, spleen, testes, lungs, predominantly in visceral 
and subcutaneous adipose tissue (22, 23). Apart from fat 
cells, a significant source of visfatin are macrophages 
which were found in fat cells and in the submucosis of 
bowel wall (24, 25). Visfatin was considered an proin-
flammatory adipokine, and visfatin expression in neutro-
phils of peripheral blood is responsible for the stimulation 
of inflammatory factors such as TNF-a (26). Research 
suggest that elevated levels of visfatin in obese children 
presents good “surrogate marker” for visceral obesity in 
children and as for later atherosclerosis as adults (27), but 
it is still a question what are the „normally“ visfatin serum 
values in early childhood and what relation it has to phys-
iological process in healthy eutrophic and obese children. 
The aim of the present study was to determine visfatin 
serum concentration at the early age in eutrophic and 
overweight/obese male children and its relation to arte-
rial blood pressure.
mATERIAlS ANd mEThodS 
The study was a prospective cohort study conducted at 
the University Hospital Center of Osijek, at the Depart-
ment of Surgery, Clinical Department of Pediatric Sur-
gery. Study protocol was in a timely manner reported to 
the Ethical Committee of the Clinical Hospital Centre 
Osijek and Ethical Committee of Faculty of Medicine 
University of Osijek, approved by the same committes. 
Parents of involved subjects were informed about the re-
search and its protocol and they gave us written consent 
for participation.
Patients
31 boys aged from 2 to 14 year were included in this 
study. All patients were hospitalized for elective inguinal 
hernia surgery at the Department of Paediatric Surgery. 
Including criteria for the study were: children who were 
matured and from regular pregnancy and delivered by 
natural birth, until now according to previously taken 
anamnestic data without serious illnesses and without 
previous surgical procedures. This study hasn’t involved 
the children who had inguinal hernia incarceration. The 
parents in anamnesis did not suffer from chronic diseases 
(diabetes, hypertension, metabolic syndrome). Exclusion 
criteria for the study were: preterm birth and prematurity, 
previous surgery, children who have diabetes or they con-
stantly are taking medications for chronic diseases (epi-
lepsy, bronchial asthma etc.). Subjects were divided into 
two groups according to body weight expressed in per-
centiles: regular body weight (percentile 5.th to 85.th) and 
overweight/obese (above 85.percentile) (28).
Anthropometric and biochemical data
In all participants anthropometric and biochemical 
measurements were preformed. Anthropometric measure-
ments included measurement of body height (measured 
by measuring tape in centimetres), body weight (measured 
in kilograms), the waist circumference (measured by mea-
suring tape in the projection of the umbilicus) and cir-
cumference of hips (measured by the measuring tape in 
the field below the big trochanter). BMI was calculated by 
formula: weight/squared projected through the percentile 
curve. Venous blood samples were taken for biochemical 
analysis: complete blood cell count, C-reactive protein, 
fasting serum glucose, total cholesterol, LDL, HDL, tri-
glycerides, urea, creatinine levels. Laboratory values were 
all done on the appliance AU 480 (Beckman Coulter, 
Brea, CA, USA). Blood pressure included measuring 
blood pressure with kid sleeves manometer (with 5 cm), 
at admission and during hospitalization three times at day.
Serum visfatin concentrations
During elective surgery, just before the anaesthetic 
procedure, venous blood samples were taken to determine 
the concentration of visfatin by standard laboratory tech-
nique. The total concentration of visfatin in serum was 
determined by enzymatic ELISA immunoassay test (Fe-
nix Pharmaceuticals, Inc., Belmont, CA, USA). The in-
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traassay coeffieient is <10% and interassy coeffitient is 
<15%.
Statistical analysis
For statistical analysis was used  descriptive statistics. 
Data are presented as mean ± SD. All statistical tests were 
two-sided and carried out at a significance level (P) of 
0.05. Shapiro-Wilks test of normality was used to test 
distribution of variables in both group of patients. Ac-
cording to results of Shapiro-Wilks test we used nonpara-
metric Mann-Whitney test. Spearman method was used 
to assess univariate relations. The value P<0.05 was con-
sidered statistically significant. Statistical analysis was 
performed by using Statistica program packages and sta-
tistical program R.
RESulTS
Characteristics for both groups of examiners are given 
in Table 1. All the patients were children without signifi-
cant differences in their body build except their body fat 
status. They all had normal fasting blood glucose level and 
serum creatinine in the morning, without glucose intoler-
ance and impaired renal function. 
By analysis of obtained values in both groups of re-
spondents (eutrophic-E and overweight/obese-O/O) 
wasn’t found to be statistically significant differences in 
the individual components of the lipid profile: cholesterol 
level (p=0.285); triglycerides (p=0.671); LDL (p=0,334); 
HDL (p= 0,236). It was also not found differences in 
fasting glucose in both groups of respondents, p = 0.356. 
CRP were higher in the group of overweight/obese chil-
dren, however, not statistically significant compared to 
eutrophic, p=0.095. 
Results of visfatin concentration amounts in the serum 
were 6.90±3.97 ng/ml in eutrophic boys and 7.82±3.75 
ng/ml in overweight/obese boys with p = 0.57. Visfatin 
values in the group of overweight/obese were elevated but 
not statistically significant (Figure 1). 
Overweight/obese children had significantly higher 
systolic blood pressure compared to eutrophic children 
(105 mmHg compared to 97 mmHg, p=0.028). Dia-
stolic pressure showed no difference in both groups, 
(E:67mmHg, O/O:72mmHg, p=0.129). Relation be-
tween visfatin concentration with systolic and diastolic 
blood pressure (BP) in eutrophic group of patients showed 
positive relation without statistical significance (systolic 
BP/visfatin, p=0.167, diastolic BP/visfatin, p=0.454), 
while systolic and diastolic BP in overweight/obese 
showed negative correlation without statistical signifi-
cance (systolic BP/visfatin, p=0.368, diastolic BP/visfatin, 
p= 0.435) (Figure 2).
According to Spearman coeffitient, there were no sta-
tistically significant correlation in overweight/obese group 
between serum visfatin level and weight (p=0.258), BMI 
(p=0.160), waist circumference (p=0.623), cholesterol 
(p=0.626), triglycerides (p=0.369), LDL (p= 0.583), HDL 
(p=0.115). All reported relation between serum visfatin 
level with anthropometric parameters and lipidogram 
profile, except for HDL, showed negative relation. In the 
eutrophic group of patients, there was statistically sig-
TAble 1




Age (years) 3,02 ± 1,32 5,67 ± 2,63
Weight (kg)* 16,94 ± 4,55 30,75 ± 14,62
Height (cm)* 103,90 ± 13,50 117,18 ± 24,05
Waist circumference (cm)* 50,36 ± 5,29 62,12 ± 16,45
Hip circumference (cm)* 30,77 ± 4,11 42,00 ± 10,39
Body mass index (kg/m2)* 15,26 ± 1,53 20,94 ± 3,80 
Percentile value 29,09 ± 23,71 94,56 ± 2,30
Morning glucose level 
(mmol/L) 4,61 ± 0,75 4,81 ± 0,50
Cratinine level (µmol/L) 30,68 ± 8,26 36,98 ± 13,89
C reactive proteine (mg/L) 0,50 ± 0,49 0,96 ± 0,85
Cholesterol (mmol/L) 4,10 ± 0,87 4,46 ± 0,89
LDL (mmol/L) 2,47 ± 0,72 2,83 ± 1,01
HDL (mmol/L) 1,29 ± 0,22 1,38 ± 0,25
Triglycerides (mmol/L) 0,81 ± 0,38 0,77 ± 0,19
Systolic BP (mmHg)* 97,27 ± 9,47 105,00 ± 13,66
Diystolic (mmHg) 67,50 ± 9,22 72,18 ± 8,75
*p < 0,05
Figure 1. Serum visfatin level in eutrophic and overweight/obese 
male children.
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nificant correlation between waist circumference and 
serum visfatin level (p=0.012). Also, there were no sig-
nificant correlation in eutrophic group between visfatin 
level and weight (p=0.069), BMI (p=0.263), cholesterol 
(p=0.134), triglycerides (p=0.362), LDL (p=0.196), HDL 
(p=0.125), except for triglycerides, all parameters had 
positive relation.
dISCuSSIoN
The main results of this study are values of visfatin 
serum concentrations in male eutrophic and overweight/
obese midle-european children in early childhood, and 
it’s relation to anthropometric parameters, systolic and 
diastolic blood pressure and metabolic profile.
According to the few previous research, most studies 
in children age have tried to explain the relationship be-
tween obesity with atherosclerotic-metabolic disease in 
later adult age, but it is still unknown the value of visfatin 
in an early age, what are the referent values and what ef-
fect obesity has on visfatin serum concentration in rela-
tion to anthropometric parametars and metabolic profile, 
which was the main purpose of this study (27-34). Some 
studies have shown association with elevated visfatin con-
centrations in children serum and its correlation with 
diseases such as diabetes mellitus, metabolic syndromes 
and obesity (29-30).
In the literature, studies from 2006-2013 showed dif-
ferent values of visfatin blood values levels in eutrophic 
and obese children (Table 2). The differences in values of 
serum visfatin can be explained with unstandardized 
laboratory procedures, due to use of different kits for de-
termination of visfatin, but probably greater impact had 
a racial differences of treated subjects. In our study, we 
compared the values of visfatin in healthy male children 
with no previous illness history with the difference in 
body mass. The obtained values results of visfatin are dif-
ferent compared to other studies, which can be explained 
with racial and gender differences, with level of obesity 
and age of included patients.
Studies that have investigated the relationship between 
visfatin levels in serum and obesity in childhood gave the 
opposite conclusions. Davutoglu et al. referring positive 
Figure 2. Correlation between systolic and diastolic blood pressure with serum visfatin concentration in eutrophic and overweight/obese exam-
inees.
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correlation between visfatin levels and obesity and ab-
dominal volume ratio of waist/hip (WHR) (32). Haider 
published a study that found twice a bigger value of vis-
fatin in obese children than in the control group, but 
found no correlation with anthropometric measures, 
CRP and lipid profile29. With a study carried out on Chi-
nese adolescents it was noted a significant positive correla-
tion between visfatin and HDL cholesterol (33). Taskesen 
proved the elevated levels of visfatin in obese children 
between the ages of 9-17 years but not the correlation with 
body weight, BMI and WHR (34). Korean studies at pre-
puberty children demonstrated that visfatin was higher 
in male children with overweight in comparison to girls, 
and that the level of visfatin in serum is positively corre-
lated with BMI and triglycerides in children with over-
weight (26). In our study, in overweight/obese group there 
was negative relation between visfatin level and anthro-
pomethric and lipide profile parameters, which can be 
explained by functional healthy fat tissue in this early life 
time even in group of patients with increased body fat. 
Also, systolic and diastolic BP in overweight/obese pa-
tients showed negative relation to visfatin level, so the 
question is what the visfatin role is in future obesity -re-
lated hypertension development? Visfatin is produced 
predominantly by visceral fat tissue, which groves by time 
(adults), stimulating proinflammatory cytokines produc-
tion. Cytokines affect vascular function and cause endo-
thelial dysfunction, presenting important part of complex 
pathophysiologic mechanism of hypertension in adults 
(35, 36).
Children’s obesity is still not sufficient explored area 
and the presence of visfatin in serum in early childhood. 
These results contribute to world knowledge about visfa-
tin level in early childhood with need for further investi-
gation because of various influences and possible gender 
differences on serum visfatin concentrations, although the 
limit of this study is small sample size. We can conclude 
that visfatin levels in serum increases with increasing of 
body weight, but also that obesity alone is not a unique 
causative factor that affects the increase of its concentra-
tion. Our results can be explained by the fact that the 
physiological and phatophysiological processes of obesity 
are highly complex, metabolic-inflammatory character 
with subsequently proatherosclerotic risk that is not man-
ifested in an early development age, probably as a result 
of still present healthy functioning of adipose tissue with-
out inflammation. One of the first cardiometabolic effects 
of obesity influence at early childhood could be the effect 
on the increasing blood pressure (systolic), since it is well 
known pathophysiological impact of obesity on hyperten-
sion development. Further studies of childhood obesity, 
the adipose tissue dysfunction and neurohormonal ac-
tivities are necessary at early childhood together with 
recognizing the risks for later developing of disease in 
adulthood. We can conclude that in the early age, fat tis-
sue has not yet developed a pathological activity in full 
scale, as has been shown for adults (23). The visfatin lev-
els in our study showed different correlation in eutrophic 
and overweight/obese patients and need for further inves-
tigation in this area suggesting possible role of visfatin in 
future metabolic and cardiovascular processes related 
with body mass. 
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